Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does GLIMEPIRIDE Cause Left ventricular dysfunction? 5 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Left ventricular dysfunction have been filed in association with GLIMEPIRIDE (Glimepiride). This represents 0.1% of all adverse event reports for GLIMEPIRIDE.

5
Reports of Left ventricular dysfunction with GLIMEPIRIDE
0.1%
of all GLIMEPIRIDE reports
0
Deaths
5
Hospitalizations

How Dangerous Is Left ventricular dysfunction From GLIMEPIRIDE?

Of the 5 reports, 5 (100.0%) required hospitalization, and 1 (20.0%) were considered life-threatening.

Is Left ventricular dysfunction Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for GLIMEPIRIDE. However, 5 reports have been filed with the FAERS database.

What Other Side Effects Does GLIMEPIRIDE Cause?

Hypoglycaemia (1,403) Blood glucose increased (446) Acute kidney injury (339) Drug ineffective (339) Diarrhoea (257) Blood glucose decreased (232) Lactic acidosis (219) Glycosylated haemoglobin increased (214) Diabetes mellitus inadequate control (213) Hypoglycaemic coma (187)

What Other Drugs Cause Left ventricular dysfunction?

DOXORUBICIN (430) CYCLOPHOSPHAMIDE (426) TRASTUZUMAB (401) CLOZAPINE (231) SACUBITRIL\VALSARTAN (231) BISOPROLOL (225) PERTUZUMAB (207) RITUXIMAB (202) DOCETAXEL (199) VINCRISTINE (193)

Which GLIMEPIRIDE Alternatives Have Lower Left ventricular dysfunction Risk?

GLIMEPIRIDE vs GLIMEPIRIDE\ROSIGLITAZONE GLIMEPIRIDE vs GLIPIZIDE GLIMEPIRIDE vs GLIVEC GLIMEPIRIDE vs GLOFITAMAB GLIMEPIRIDE vs GLOFITAMAB-GXBM

Related Pages

GLIMEPIRIDE Full Profile All Left ventricular dysfunction Reports All Drugs Causing Left ventricular dysfunction GLIMEPIRIDE Demographics